VOQUEZNA TRIPLE PAK Drug Patent Profile

When do Voquezna Triple Pak patents expire, and what generic alternatives are available?

Voquezna Triple Pak is a drug marketed by Phathom and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and three patent family members in forty-three countries.

The generic ingredient in VOQUEZNA TRIPLE PAK is amoxicillin; clarithromycin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; vonoprazan fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Voquezna Triple Pak

Voquezna Triple Pak will be eligible for patent challenges on May 3, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 3, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VOQUEZNA TRIPLE PAK

International Patents:	103
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for VOQUEZNA TRIPLE PAK
DailyMed Link:	VOQUEZNA TRIPLE PAK at DailyMed

See drug prices for VOQUEZNA TRIPLE PAK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VOQUEZNA TRIPLE PAK

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

215152

Dosage:

CAPSULE, TABLET, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VOQUEZNA TRIPLE PAK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1

See all VOQUEZNA TRIPLE PAK clinical trials

US Patents and Regulatory Information for VOQUEZNA TRIPLE PAK

VOQUEZNA TRIPLE PAK is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes	7,977,488			Y
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes	9,186,411		Y
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes

International Patents for VOQUEZNA TRIPLE PAK

When does loss-of-exclusivity occur for VOQUEZNA TRIPLE PAK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Japan

Malaysia

Mexico

Morocco

New Zealand

Peru

Singapore

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VOQUEZNA TRIPLE PAK around the world.

Country	Patent Number	Title	Estimated Expiration
Morocco	29773
European Patent Office	1919865
South Korea	20110042334	PHARMACEUTICAL COMPOSITION
Serbia	52473
Japan	2011529445

Market Dynamics and Financial Trajectory for VOQUEZNA TRIPLE PAK

Last updated: February 20, 2026

What Are the Key Market Drivers for VOQUEZNA TRIPLE PAK?

VOQUEZNA TRIPLE PAK (bupivacaine, meloxicam, and dexamethasone) is an injectable medication approved for pain management in surgical procedures. Its market growth hinges on several factors:

• Increasing demand for multimodal pain management regimens reduces reliance on opioids.
• Rising outpatient surgeries escalate the need for non-opioid long-lasting analgesics.
• Favorable reimbursement policies in North America and Europe support adoption.
• Growing awareness of post-surgical pain control benefits bolsters utilization.

Data indicates that the global surgical analgesics market is expected to grow at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2027 [1].

What Is the Current Market Position and Competitive Landscape?

VOQUEZNA TRIPLE PAK was approved by the FDA in 2022. Key competitors include other multi-agent local anesthesia formulations and single-agent local anesthetics.

Competitor / Product	Composition	Market Status	Approximate Market Share (2023)
Exparel (bupivacaine liposome)	Liposomal bupivacaine	Established, niche	15%
Zynrelef (bupivacaine+dexamethasone)	Bupivacaine and dexamethasone	Growing, targeted use	10%
Generic bupivacaine	Bupivacaine alone	Widely used, competitive	50%
VOQUEZNA TRIPLE PAK	Bupivacaine + meloxicam + dexamethasone	Newly launched	5%

Market share for VOQUEZNA TRIPLE PAK remains limited, but initial uptake shows an upward trend, driven by clinician preference for multimodal pain management.

What Are the Key Revenue and Sales Projections?

Initial sales forecasts following launch anticipate approximately $50 million in 2023, with a growth rate based on expanding clinical adoption and geographic expansion.

Year	Estimated Revenue	Growth Rate	Assumptions
2023	$50 million	—	Launch phase, early prescriber acceptance
2024	$75 million	50%	Increased market penetration, expanded payer coverage
2025	$120 million	60%	Broader adoption, new indications

These projections rely on an estimate of increased surgical procedures and clinicians switching from mono-agent therapies.

What Are the Regulatory and Market Access Challenges?

• The drug’s label approval was specific to certain surgical procedures; expanding indications requires additional trials.
• Insurance and payer coverage remain inconsistent for multimodal analgesics.
• Adoption depends on clinician education and clinical evidence demonstrating superiority over existing standards.
• Competition from established products like Exparel and generic alternatives affects pricing and market share.

How Does Patent and Intellectual Property Impact Future Growth?

VOQUEZNA TRIPLE PAK's patent protections extend to 2027, with some formulations protected until 2029. Patent expirations could enable generic competition, pressuring prices and margins.

What Are the Opportunities for Expansion?

• Efficacy in other postoperative pain settings. Clinical trials are underway for abdominal and orthopedic procedures.
• Geographic expansion into emerging markets with increasing surgical volumes.
• Development of combination formulations to streamline administration.

What Is the Overall Financial Trajectory?

The financial trajectory suggests a gradual increase in sales, constrained initially by adoption hurdles but benefiting from ongoing clinical validation and expanded indications.

• Break-even may occur between 2024 and 2025.
• Margins are expected to improve as production scales and competition intensifies, with gross margins projected at 65-70% by 2025.
• Investment in sales force and educational outreach will be key to accelerating adoption.

Key Takeaways

• VOQUEZNA TRIPLE PAK enters a growing multimodal analgesic market driven by surgical volume increases and opioid reduction efforts.
• Market share remains limited but is poised for growth with expanding clinical evidence and geographic reach.
• Revenue estimates forecast a significant acceleration from $50 million in 2023 to over $120 million by 2025.
• Competition and patent expiration present risks; strategic expansion and clinical validation are vital for profitability.
• Regulatory hurdles and payer coverage influence immediate market penetration.

FAQs

What factors influence VOQUEZNA TRIPLE PAK’s market adoption?
Clinical efficacy data, clinician familiarity with multimodal approaches, payer coverage policies, and marketing efforts.

When is the peak sales period expected?
Between 2024 and 2026, contingent on clinical trials demonstrating broader effectiveness and successful market expansion.

What are the primary competitors?
Exparel (liposomal bupivacaine), Zynrelef (bupivacaine+dexamethasone), and generic bupivacaine.

How does patent protection influence future pricing?
Patent expirations may allow generics, which could reduce prices and profit margins.

What are the primary risks to revenue growth?
Delayed clinical adoption, regulatory hurdles, payer restrictions, aggressive pricing by competitors, and patent expiration.

---

References

[1] Market Research Future (2022). Surgical analgesics market forecast. Retrieved from https://www.marketresearchfuture.com